GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Selling and Marketing Expense

JWCTF (JW (Cayman) Therapeutics Co) Selling and Marketing Expense : $10.61 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. JW (Cayman) Therapeutics Co's Selling and Marketing Expense for the six months ended in Jun. 2024 was $7.15 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2024 was $10.61 Mil.

JW (Cayman) Therapeutics Co Selling and Marketing Expense Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Selling and Marketing Expense Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling and Marketing Expense
Get a 7-Day Free Trial - 2.03 26.81 11.51 7.46

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.17 7.50 3.99 3.46 7.15

JW (Cayman) Therapeutics Co Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $10.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Selling and Marketing Expense
Comparable Companies
HKSE:02197 HKSE:02185 HKSE:06996 HKSE:06998 HKSE:03681 HKSE:01228 HKSE:02142 HKSE:09939 HKSE:01875 HKSE:00690 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
02126:Hong Kong JNY:Germany
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
Website
https://www.jwtherapeutics.com
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co Headlines

No Headlines